Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

global health inequality

- PMLiVE

Growing evidence supports the important role of biosimilars in healthcare

New data released at the ASCO Quality Care Symposium continues to underscore the cost-effectiveness of biosimilar treatment options in cancer care

- PMLiVE

Novartis’ Sandoz division announces antibiotic manufacturing plan

Joint investment agreed with the Austrian federal government

- PMLiVE

Sandoz admits antitrust crime, pays $195m in penalties

Biggest payout in US legal history for this type of criminal activity

- PMLiVE

Ex-Sandoz exec admits role in generic drug price-fixing plot

Reignites criticism of high drug prices in the US

- PMLiVE

Will biosimilars ever catch on in the US?

Why biosimilars are viewed in the US as ‘me too’ drugs rather than as just-as-good alternatives to branded products

- PMLiVE

Roche posts minor sales miss in Q4 as biosimilar pressure grows

Swiss pharma still managed an 8% increase in pharma sales

- PMLiVE

Sandoz expands into Japan with €400m Aspen deal

Will gain presence in third largest generics market in the world

- PMLiVE

Sandoz finally wins FDA approval for Neulasta biosimilar

Follows a three year wait since initial rejection in 2016

- PMLiVE

GSK and Apotex join generic Zantac recalls as carcinogen concerns mount

Novartis’ generic unit Sandoz halted distribution last week

- PMLiVE

Distribution of Novartis’ generic Zantac halted due to carcinogen concerns

Ranitidine medicines found to contain cancer-causing substance

Novartis building

Novartis expands its generics franchise with natalizumab biosimilar

Says affordability is a challenge to access

- PMLiVE

Amgen wins Enbrel patent case, knocking back Sandoz’s biosimilar plan

Shares up 6% following court ruling

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links